Washington University

CENTER FOR LARGE-SCALE GENOME SEQUENCING & ANALYSIS

GLYCEMIA REDUCTION APPROACHES IN DIABETES: A COMPARATIVE EFFECTIVENESS STUDY

DATA COORD. CENTER - NICHD COOPERATIVE MULTICENTER MATERNAL FETAL MEDICINE UNITS

STATISTICS CENTER FOR PEDIATRIC TYPE 2 DIABETES THERAPY

THE LONG LIFE FAMILY STUDY

WU ICTS - RESOURCE DEVELOPMENT TO FACILITATE SIRB REVIEW FOR MULTI-SITE RESEARCH

CANCER CENTER SUPPORT GRANT

DIAN-TU: TAU NEXT GENERATION PREVENTION TRIAL

DIAN-TU PRIMARY PREVENTION TRIAL

A PLATFORM FOR LARGE-SCALE DISCOVERY IN COMMON DISEASE

AIDS AND CANCER SPECIMEN RESOURCE (ACSR)

DATA COORDINATING CENTER (DCC) FOR COMPLETION OF ONGOING MFMU NETWORK PROTOCOLS (U24 CLINICAL TRIAL OPTIONAL) - PROJECT SUMMARY/ABSTRACT THE EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT MATERNAL-FETAL MEDICINE UNITS (MFMU) NETWORK WAS CREATED IN 1986 TO CONDUCT CLINICAL RESEARCH STUDIES IN OBSTETRICS AND PERINATAL MEDICINE. THE MFMU NETWORK CONSISTS OF A NUMBER OF MAJOR ACADEMIC CLINICAL CENTERS, A DATA COORDINATING CENTER (DCC), AND THE NICHD. THE RESEARCH STUDIES, RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES, ARE AIMED AT REDUCING MATERNAL, FETAL AND INFANT MORBIDITY RELATED TO PRETERM BIRTH, FETAL GROWTH ABNORMALITIES AND MATERNAL COMPLICATIONS, AND TO PROVIDE THE RATIONALE FOR EVIDENCE-BASED, COST-EFFECTIVE, OBSTETRIC PRACTICE. THE MFMU NETWORK STRUCTURE ALLOWS STUDIES TO BE COMPLETED IN A MORE RIGOROUS FASHION AND MORE EFFICIENTLY THAN INDIVIDUAL MULTI-CENTER PROJECTS. TO FULFILL THIS MISSION, THE MFMU NETWORK IS CURRENTLY CONDUCTING SIX RANDOMIZED TRIALS, THREE OBSERVATIONAL STUDIES, AND TWO LONG-TERM FOLLOW-UP STUDIES OF CHILDREN. THESE STUDIES ARE A REFLECTION OF THE URGENT CLINICAL ISSUES OF TODAY INCLUDING PREMATURITY, MATERNAL PREGNANCY RELATED MORBIDITY, THE OPIOID CRISIS AND THE COVID- 19 PANDEMIC. THE DCC IS A CRITICALLY IMPORTANT PART OF THIS COLLABORATIVE EFFORT AND A VITAL PART OF ENSURING THESE STUDIES ARE COMPLETED ON TIME AND WITH INTEGRITY. THE OVERALL PURPOSE OF THE DCC IS TO MAKE SURE THAT THE STUDIES ARE DESIGNED TO MINIMIZE BIAS, ARE CONDUCTED USING RIGOROUS PROTOCOLS, AND THE RESULTS ANALYZED AND INTERPRETED APPROPRIATELY TO ENSURE THE VALIDITY OF THE CONCLUSIONS. THE AIMS OF THE DCC ARE TO PROVIDE SCIENTIFIC AND BIOSTATISTICAL EXPERTISE IN MATERNAL FETAL MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS TO ADDRESS THE KEY SCIENTIFIC QUESTIONS. THE DCC WILL CONDUCT INTERIM ANALYSES FOR THE DATA AND SAFETY MONITORING BOARD, COLLABORATE WITH MFMU INVESTIGATORS ON STATISTICAL ANALYSES AND THE DISSEMINATION OF STUDY RESULTS, AND SHARE DATASETS AND RESOURCES. THE DCC WILL PROVIDE A FLEXIBLE DATA MANAGEMENT SYSTEM AND COLLABORATE WITH THE MFMU INVESTIGATORS ON THE CONDUCT AND MONITORING OF EACH STUDY INCLUDING TRAINING, MAINTENANCE OF STUDY DOCUMENTS, AND REPORTING TO THE STEERING COMMITTEE AND FOOD AND DRUG ADMINISTRATION. LASTLY, THE DCC WILL COORDINATE COMMUNICATION THROUGH BOTH PRIVATE AND PUBLIC WEBSITES, AND PROVIDE THE LOGISTICAL AND ADMINISTRATIVE SUPPORT TO THE OVERALL NETWORK ORGANIZATION NECESSARY TO RUN EFFICIENT AND PRODUCTIVE STUDIES. THROUGH EFFECTIVE ORGANIZATION, COMMUNICATION, AND LOGISTICAL, TECHNICAL AND SCIENTIFIC SUPPORT, THE DCC WILL CONTINUE TO PROVIDE THE FRAMEWORK FOR THE MFMU NETWORK TO ADDRESS THE KEY SCIENTIFIC QUESTIONS OF THE ONGOING STUDIES.

POST DPP FOLLOW UP STUDY: DATA COORDINATING CENTER

MRCE FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES

GENOMICS OF ACUTE MYELOGENOUS LEUKEMIA

FLAVIVIRUS AND ALPHAVIRUS REVAMPP (FLARE) - SUMMARY. THE FLAVIVIRUS AND ALPHAVIRUS REVAMPP (FLARE) CENTER WILL DEVELOP AND OPTIMIZE PROTEIN NANOPARTICLE, VIRION-BASED, AND MRNA VACCINE PLATFORMS, AND MONOCLONAL ANTIBODY (MAB)-BASED TREATMENTS TO RAPIDLY RESPOND TO EMERGING FLAVIVIRUSES AND ALPHAVIRUSES WITH PANDEMIC POTENTIAL. A KEY GOAL IS TO PAIR SPECIFIC ANTIGEN DESIGNS AND VACCINE PLATFORMS SO THAT SUCCESSFUL PARADIGMS CAN BE RAPIDLY ADAPTED IN A “PLUG AND PLAY” MANNER TO EMERGING VIRUSES WITHIN THE SAME FAMILY. OUR SUITE OF ANTIGEN DESIGN STRATEGIES, VACCINE PLATFORMS, STATE-OF-THE-ART VIROLOGICAL AND IMMUNOLOGICAL ASSAYS, EXTENSIVE ANIMAL MODEL EXPERIENCE, DETAILED ANALYSIS OF CORRELATES OF PROTECTION, AND EXPERIENCED INDUSTRY PARTNERS (E.G., MODERNA) WILL ENABLE US TO GENERATE INNOVATIVE VACCINES AND MAB COMBINATIONS AGAINST KEY TARGETED PROTOTYPE FLAVIVIRUSES AND ALPHAVIRUSES, WHICH THEN CAN BE APPLIED TO RELATED NEW THREATS. MOREOVER, WITH OUR COLLECTIVE ACADEMIC EXPERIENCE IN VACCINOLOGY AND COLLABORATIVE EXPERIENCE WITH INDUSTRY PARTNERS, WE CAN MAKE INFORMED GO/NO-GO DECISIONS TO FOCUS ON ANTIGENS AND VACCINES WITH THE GREATEST CHANCE FOR CLINICAL EFFICACY AND SAFETY. OUR FLARE CENTER INTEGRATES THE WORK OF MULTIPLE ACADEMIC GROUPS, WITH PROVEN RECORDS OF COLLABORATION, THAT HAVE THE HIGHEST LEVELS OF EXPERTISE IN FLAVIVIRUS AND ALPHAVIRUS BIOLOGY, ANTIGEN DESIGN, STRUCTURAL BIOLOGY, ANTIBODY STRUCTURE AND FUNCTION, MAB GENERATION AND CHARACTERIZATION, VACCINE DEVELOPMENT, B AND T CELL IMMUNITY, FC EFFECTOR FUNCTIONS, AND ANIMAL CHALLENGE STUDIES, ALL WORKING TOWARD THE GOAL OF DESIGNING OPTIMIZED IMMUNOGENS FOR INCORPORATION INTO LIPID-ENCAPSULATED MRNA, NANOPARTICLES, OR OTHER VECTORS TO CREATE VACCINES THAT CAN PROTECT AGAINST INFECTION AND DISEASE CAUSED BY EXISTING AND FUTURE FLAVIVIRUS AND ALPHAVIRUS THREATS. OUR FLARE CENTER IS COMPOSED OF FIVE PRIMARY RESEARCH PROJECTS: TWO VACCINE PROJECTS THAT COLLECTIVELY FOCUS ON PROTOTYPE FLAVIVIRUSES INCLUDING WEST NILE (WNV), TICK-BORNE ENCEPHALITIS (TBEV), AND DENGUE (DENV) VIRUSES; TWO VACCINE PROJECTS, THAT FOCUS ON PROTOTYPE ALPHAVIRUSES INCLUDING CHIKUNGUNYA (CHIKV) AND VENEZUELAN EQUINE ENCEPHALITIS (VEEV) VIRUSES; AND A MAB THERAPY PROJECT THAT FOCUSES ON BOTH FLAVIVIRUSES (WNV AND DENV) AND ALPHAVIRUSES (CHIKV). THESE PROJECTS ARE SERVED BY AN ADMINISTRATIVE CORE, A DATA MANAGEMENT CORE, AND THREE SCIENTIFIC CORES THAT PERFORM STRUCTURAL BIOLOGY AND PROTEIN ENGINEERING, ANIMAL VACCINATION AND CHALLENGE, AND CORRELATES OF IMMUNE PROTECTION EXPERIMENTS IN COLLABORATION WITH MULTIPLE PROJECTS. OUR NETWORK OF EXPERT INVESTIGATORS, INNOVATIVE PROJECT AND CORES, AND STATE-OF-THE ART VIROLOGICAL AND IMMUNOLOGICAL APPROACHES WILL ENABLE US TO DEVELOP VACCINE AND MAB THERAPEUTICS AGAINST PROTOTYPE FLAVIVIRUSES AND ALPHAVIRUSES THAT CAN BE READILY AND RAPIDLY APPLIED TO OTHER CONTEMPORARY AND NEWLY EMERGING RELATED VIRAL THREATS.

HEALTHY AGING AND SENILE DEMENTIA

DOMINANTLY INHERITED ALZHEIMER NETWORK

VACCINES AND THERAPEUTIC ANTIBODIES TO RESPIRO, RUBULA, PERIBUNYA AND PHENUIVIRIDAE (R2P2)-REVAMPP - SUMMARY. THE VACCINES AND THERAPEUTIC ANTIBODIES TO RESPIROVIRUS, RUBULAVIRUS, PERIBUNYAVIRUS AND PHENUIVIRUS (R2P2) REVAMPP CENTER WILL UTILIZE BOTH WELL-DEFINED AND NOVEL APPROACHES TO DEVELOP PROTOTYPE VACCINES AND HUMAN MONOCLONAL ANTIBODY (MAB)-BASED TREATMENTS FOR RAPID RESPONSE TO VIRUSES FROM THE PARAMYXOVIRIDAE, PERIBUNYAVIRIDAE AND PHLEBOVIRIDAE FAMILIES. R2P2 IS COMPOSED OF FOUR PRIMARY RESEARCH PROJECTS: TWO THAT COLLECTIVELY FOCUS ON PROTOTYPE VIRUSES OF THE PARAMYXOVIRIDAE FAMILY INCLUDING HUMAN PARAINFLUENZA VIRUSES 3 AND 1 (HPIV3, HPIV1), AND HUMAN AND BAT MUMPS VIRUS (MUV, BATMUV); AND TWO THAT FOCUS ON PROTOTYPE VIRUSES OF THE BUNYAVIRALES ORDER INCLUDING THE PERIBUNYAVIRIDAE OROPOUCHE (OROV) AND LA CROSSE (LACV) AND THE PHENUIVIRIDAE RIFT VALLEY FEVER VIRUS (RVFV) AND TOSCANA VIRUS (TOSV). EACH PROJECT IN R2P2 FOLLOWS A PARALLEL STRUCTURE AND MAKES USE OF THE PRINCIPLES OF REVERSE VACCINOLOGY, WHERE INSIGHTS FROM THE STRUCTURAL AND FUNCTION STUDIES WILL PROVIDE A FRAMEWORK TO UNDERSTAND THE MOLECULAR CORRELATES OF IMMUNITY AND ANTIGENICITY AND PROVIDE A ROADMAP FOR DESIGNING OPTIMIZED IMMUNOGENS. THE FOUNDATIONAL STUDIES CARRIED OUT IN THIS REVAMPP CENTER WILL FILL GAPS IN BASIC UNDERSTANDING OF VIRAL ENTRY AND WILL ALSO INFORM HOW TO EXTEND THE STABILIZATION APPROACHES SUCCESSFULLY USED TO ADVANCE VACCINES AGAINST AGENTS WITH CLASS I FUSOGENS (E.G., RSV), TO THOSE WITH CLASS II. A KEY R2P2 FEATURE IS THAT ALL FOUR PROJECTS COMPARE THE SAME THREE VACCINE PLATFORMS: PROTEIN SUBUNIT, MRNA, AND CHIMERIC VSV, ALLOWING FOR CROSS COMPARISONS THAT WILL RAPIDLY YIELD INFORMATION ABOUT PLATFORM PERFORMANCE IN TRANSLATING TO RELATED PATHOGENS. THE QUESTIONS OF WHICH ANTIGEN STABILIZATION PARADIGMS, AND WHICH VACCINE PLATFORMS ARE MOST AMENABLE TO GENERALIZING FROM THE PROTOTYPE PATHOGENS WILL BE ANSWERED IN DEPTH AND BREADTH BY THESE COMPARISONS ACROSS VIRUS FAMILIES. WE ASSEMBLED A COLLABORATIVE TEAM OF WORLD-RENOWNED EXPERTS ON VIRAL ENVELOPE PROTEIN STRUCTURE AND FUNCTION, LEADING IMMUNOLOGISTS, VACCINOLOGISTS WITH EXTENSIVE EXPERIENCE IN INDUSTRY AND REGULATORY ISSUES, AND INDUSTRY PARTNERS (E.G., MODENA, GSK). THE INCLUSION OF JUNIOR INVESTIGATORS WITH EXCEPTIONAL PROMISE IS DESIGNED TO ENSURE THE ENGAGEMENT OF THE NEXT GENERATION OF LEADERS IN VIRAL GLYCOPROTEIN BIOLOGY, VIRAL IMMUNOLOGY AND VACCINOLOGY IN PANDEMIC PREPAREDNESS. THESE PROJECTS ARE SERVED BY AN ADMINISTRATIVE CORE (CORE A), A DATA MANAGEMENT CORE (CORE B), AND THREE SCIENTIFIC CORES THAT PERFORM STRUCTURAL BIOLOGY, BIOPHYSICS AND PROTEIN ENGINEERING (CORE C), ANTIBODY ISOLATION AND ASSESSMENT (CORE D), AND CORRELATES OF IMMUNE PROTECTION (CORE E) EXPERIMENTS IN COLLABORATION WITH MULTIPLE PROJECTS. THE KNOWLEDGE ACCUMULATED IN THIS PROJECT AND THE ROBUSTNESS OF THE APPROACHES IMPLEMENTED TO DEVELOP PROTOTYPE VACCINES WILL BE EXPANDED TO DIFFERENT VIRUSES OF THE SAME FAMILIES TO EVALUATE THEIR POTENTIAL AND BROAD APPLICABILITY AGAINST EMERGING VIRUSES OF THE BUNYAVIRALES ORDER AND PARAMYXOVIRIDAE FAMILY.

ANTEDECENT BIOMARKERS FOR AD: THE ADULT CHILDREN STUDY BIOMARKERS CORE

WASHINGTON UNIVERSITY INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES

PHOTOSYNTHETIC ANTENNA RESEARCH CENTER (PARC) -- EFRC

NATIONAL RESEARCH SCIENCE AWARD - MEDICAL SCIENTIST

THE DC COHORT: A LONGITUDINAL POPULATION-BASED COHORT STUDY OF PEOPLE LIVING WITH HIV IN WASHINGTON, DC

CPCRA CLINICAL TRIALS UNIT

WASHINGTON UNIVERSITY INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES (UL1)

DIAN-TU: NEXT GENERATION PREVENTION TRIAL

THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCE

MAPPING THE HUMAN CONNECTOME: STRUCTURE FUNCTION AND HERITABILITY

HEALTHY BRAIN AND CHILD DEVELOPMENT NATIONAL CONSORTIUM DATA COORDINATING CENTER - PROJECT SUMMARY THE LANDMARK HEALTHY BRAIN AND CHILD DEVELOPMENT (HBCD) STUDY WILL PROVIDE A REPRESENTATIVE REFERENCE DATA RESOURCE TO THE SCIENTIFIC COMMUNITY ENABLING UNPRECEDENTED INVESTIGATION OF NEURODEVELOPMENT AND THE IMPACT OF ENVIRONMENTAL, GENETIC, AND BIOLOGICAL FACTORS ON BRAIN AND BEHAVIORAL HEALTH AND DEVELOPMENTAL TRAJECTORIES FROM INFANCY THROUGH CHILDHOOD. THROUGH THIS STUDY, THE HEALTHY BRAIN AND CHILD DEVELOPMENT NATIONAL CONSORTIUM (HBCD-NC) WILL RECRUIT AND RETAIN A SOCIODEMOGRAPHICALLY DIVERSE COHORT OF 7,500 PREGNANT WOMEN FROM 24 SITES ACROSS THE U.S. AND FOLLOW THESE FAMILIES AND THEIR CHILDREN THROUGH THE FIRST DECADE OF LIFE. CHILDREN WILL UNDERGO RIGOROUS DATA COLLECTION ACROSS MODALITIES INCLUDING NEUROIMAGING, NEUROPHYSIOLOGY, BEHAVIORAL AND COGNITIVE ASSESSMENTS, AND COLLECTION OF BIOSPECIMENS VIA A BALANCED PROTOCOL DEVELOPED BY FIELD-LEADING EXPERTS. BUILDING UPON THE SUBSTANTIVE COMPLEMENTARY EXPERIENCE AND EXPERTISE OF ITS MULTIDISCIPLINARY TEAM AND LEVERAGING MULTIPLE POPULATION-SPECIFIC TECHNICAL INNOVATIONS, THE HEALTHY BRAIN AND CHILD DEVELOPMENT NATIONAL CONSORTIUM DATA COORDINATING CENTER (HDCC) WILL PROVIDE THE LEADERSHIP, MANAGEMENT, AND OVERSIGHT OF DATA COLLECTION, QUALITY CONTROL, CURATION, PROCESSING, MANAGEMENT, SHARING, AND ANALYTICS TO FACILITATE AND SUPPORT THE ACTIVITIES OF THE HBCD-NC AND ENSURE ITS SUCCESS. INCLUDED IS DEVELOPMENT AND IMPLEMENTATION OF AN OPTIMIZED, STATE-OF-THE-ART MRI PROTOCOL HARMONIZED FOR THE FIRST TIME IN INFANTS/TODDLERS ACROSS ALL THREE MAJOR VENDORS WHICH LEVERAGES THE LATEST INNOVATIONS IN SCANNER TECHNOLOGY WITH AGE-SPECIFIC STRUCTURAL, MICROSTRUCTURAL, QUANTITATIVE, FUNCTIONAL, AND SPECTROSCOPY SEQUENCES. ALSO DETAILED IS A TARGETED EEG PROTOCOL LINKED WITH A FIELD-LEADING AUTOMATED PROCESSING PIPELINE FOR DEVELOPMENTAL EEG WHICH PROVIDES INNOVATIVE DERIVATIVE MEASURES. DATA AND PROJECT MANAGEMENT WILL OCCUR THROUGH A CENTRALIZED TRACKING AND DISTRIBUTION PLATFORM LINKED TO A HIGH-THROUGHPUT COMPUTE BACKBONE WHICH OVERCOMES LIMITS OF COMMERCIALLY-AVAILABLE SYSTEMS FOR MANAGEMENT AND INTEGRATED PROCESSING OF MULTIMODALITY DATA FROM LARGE, MULTI-SITE STUDIES. HIGH PERFORMANCE COMPUTING WILL BE SUPPORTED THROUGH UNIQUE ACCESS TO A COMBINATION OF FIELD-LEADING RESOURCES. DETAILED PROCEDURES ARE OUTLINED FOR SECURE COLLECTION, MANAGEMENT, AND ANALYSIS OF PERSONALLY IDENTIFIABLE INFORMATION (PII) DATA, INCLUDING FLEXIBLE METHODS DESIGNED TO ACCOMMODATE HETEROGENEITY IN ELECTRONIC HEALTH RECORD SYSTEMS ACROSS SITES. FINALLY, SUBSTANTIVE HBCD-SPECIFIC ENHANCEMENTS TO THE DATA EXPLORATION AND ANALYSIS PORTAL (DEAP 2.0) WILL PRODUCE A CRUCIAL TOOL FOR DATA ACCESS TO AUTHENTICATED USERS WHILE PROMOTING BEST PRACTICES IN REPRODUCIBLE STATISTICAL ANALYSIS AND PROVIDING FLEXIBLE COMPUTATION WITHOUT THE NEED TO DOWNLOAD RESTRICTED-ACCESS DATA. THE RESULT OF THIS FIELD- LEADING COMBINATION OF HDCC RESOURCES WILL BE A STATE-OF-THE-ART, LONGITUDINAL DATA SET OF UNPARALLELED SCALE WHICH PROVIDES DEEP UNDERSTANDING OF THE BIOLOGICAL AND ENVIRONMENTAL FACTORS THAT AFFECT A CHILD’S HEALTH, BRAIN, AND BEHAVIORAL DEVELOPMENT AND SHAPES RESEARCH, CLINICAL CARE, AND PUBLIC POLICY FOR DECADES TO COME.

HIGHER EDUCATION EMERGENCY RELIEF FUND, INSTITUTIONAL PORTION

VULNERABILITY AND RESILIENCY IN THE AGING ADULT BRAIN CONNECTOME (AABC) - ABSTRACT FOR OVERVIEW THE AGING ADULT BRAIN CONNECTOME (AABC) LEVERAGES THE EXISTING INFRASTRUCTURE DEVELOPED BY THE HUMAN CONNECTOME PROJECT FOR AGING (HCP-A) BY OBTAINING LONGITUDINAL FOLLOW-UP DATA (NEUROIMAGING, COGNITIVE TESTING, AND BLOOD) USING A STANDARDIZED PROTOCOL FROM A WELL CHARACTERIZED COHORT OF OVER 1,000 HEALTHY INDIVIDUALS TO GENERATE WITHIN-PARTICIPANT BRAIN TRAJECTORIES FOR UP TO 10 YEARS. AT INITIAL RECRUITMENT, INDIVIDUALS ENROLLED IN THE HCP-A WERE GENERALLY PHYSICALLY AND COGNITIVELY HEALTHY BUT OVER TIME SOME WILL DEVELOP PRECLINICAL AD OR EARLY COGNITIVE CHANGES DUE TO AD OR ADRD. THE AABC IS COMPRISED OF FOUR PROJECTS: PROJECT 1 EXAMINE THE EFFECTS OF STRESS AND ALLOSTATIC LOAD, INCLUDING INFLAMMATION, DURING THE EARLY ADULT PERIOD. PROJECT 2 EXAMINES THE EFFECTS OF LIFESTYLE BEHAVIORS ON THE TRAJECTORY OF COGNITIVE AND BRAIN CHANGES DURING THE MID ADULT PERIOD. PROJECT 3 EXAMINE THE EFFECTS OF MENOPAUSE TRANSITION/VASOMOTOR SYMPTOMS DURING THE MID ADULT PERIOD. PROJECT 4 EXAM- INE THE CLINICAL AND NEURAL INDICATORS OF RESILIENCY AND RESISTANCE TO AD AND ADRD IN THE LATER DECADES OF ADULT- HOOD. THE AABC ALSO CONSISTS OF 4 CORES: THE ADMINISTRATION CORE (AC) WILL PROVIDE ESSENTIAL CORE AND SITE LEADERSHIP TO CARRY OUT THE SCIENTIFIC MISSION OF THE AABC. THE DIVERSITY RECRUITMENT AND RETENTION UNIT (DRRU) WILL BE LOCATED WITHIN THIS CORE AND WILL ENSURE THAT THE AABC CONTINUES TO RECRUIT AND RETAIN AN ADEQUATE DISTRI- BUTION OF RACES THAT IS CURRENTLY SEEN IN THE US. THE INTEGRATED DATA ACQUISITION CORE (IDAC) PROVIDES EXPERTISE AND PERSONNEL FROM EACH SITE TO ACQUIRE HIGH QUALITY NEUROIMAGING, DEEP PHENOTYPING OF NON-IMAGING DATA, AND BIOSAMPLES FROM EACH SITE.THE INFORMATICS, DATA ANALYSIS, AND STATISTICS CORE (IDASC) WILL HOUSE PROJECT IMAG- ING DATA USING THE INTRADB DATABASE, WILL PERFORM QUALITY CONTROL OF RAW AND ANALYZED DATA, WILL DEVELOP AND RUN CROSS-SECTIONAL AND LONGITUDINAL PIPELINES TO PRODUCE MULTI-MODAL IMAGING DATA PHENOTYPES FOR EACH PROJECT, WILL PROVIDE DIMENSION-REDUCED SUMMARIES, WILL IMPUTE MISSING DATA; AND WILL DEVELOP AND RUN STATISTICAL MODELS FOR EACH PROJECT. THE IDASC WILL ALSO BE RESPONSIBLE FOR DATA SHARING WITH THE GENERAL PUBLIC. THE GENETICS AND MULTI-OMICS SPECIMENS CORE (GMSC) WILL PROVIDE GENETIC INFORMATION ON PARTICIPANTS EVALUATED THROUGH THE AABC WHO HAVE BEEN CHARACTERIZED USING A UNIFORM PROTOCOL. MULTI-OMIC DATA AND AD BIOMARKER DATA WILL BE GENERATED BY THE GMSC.